(Albany, US), October 26, 2026 – DelveInsight’s ‘Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast – 2036’ report delivers an in-depth understanding of Parkinson’s disease, historical and forecasted epidemiology, as well as the Parkinson’s disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Explore the intricate details of the Parkinson’s Disease Market Report @ Parkinson’s Disease Treatment Market Size
Key Takeaways from the Parkinson’s Disease Market Report
In October 2026, Lundbeck presented positive Phase Ib clinical data for Lu AF28996 in patients with advanced Parkinson’s disease while announcing the initiation of a broader Phase II clinical trial, highlighting the drug’s favorable safety and pharmacokinetic profile in managing motor complications and fluctuations.
In August 2026, Lunai Bioworks finalized a definitive collaboration agreement with BrainStorm Cell Therapeutics to co-develop therapies targeting Parkinson’s disease, with an initial data readout targeted for the first half of 2027.
In June 2026, Aspen Neuroscience announced completion of dosing across Cohort 3 and Cohort 4 in its Phase 1/2a ASPIRO trial evaluating sasineprocel, a personalized autologous iPSC-derived cell therapy, for Parkinson’s disease.
The Parkinson’s Disease market size was valued at USD 3,539 million in 2025 and is anticipated to grow at a significant CAGR during the forecast period (2026-2036), driven by advancements in diagnostic techniques, increased awareness of the condition, and a rising number of reported cases.
According to DelveInsight’s analysis, the Parkinson’s Disease market in the 7MM was valued at approximately USD 3,218 million in 2023.
The Parkinson’s Disease market size in the US was approximately USD 1,883 million in 2023, while the total market size of EU4 and the UK was approximately USD 988 million, nearly 31% of the total 7MM market revenue.
Among EU4 and the UK, Germany accounted for the highest market with approximately USD 390 million in 2023, followed by France with approximately USD 218 million and the UK with USD 130 million. In Japan, the market size was approximately USD 348 million in 2023.
According to DelveInsight’s estimates, there were approximately 2,718 thousand diagnosed prevalent cases of Parkinson’s disease in the 7MM in 2023, of which the United States accounted for 45%, while Germany and Japan represented 18% and 9%, respectively.
Among currently approved therapies, the majority of the market share was held by others and combination therapies, with revenue of approximately USD 2,210 million in 2023.
Current treatments, such as levodopa and dopamine agonists, primarily manage symptoms but do not address the underlying cause of neuronal loss, leading to diminished efficacy over time and challenges such as motor fluctuations, dyskinesias, and non-motor symptoms.
The leading Parkinson’s Disease companies include Amneal Pharmaceuticals, AbbVie, Newron Pharmaceuticals, Supernus Pharmaceutical, Britannia Pharmaceuticals, Pharma Two B, UCB Biopharma SRL, Novartis, Annovis Bio, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevel Therapeutics, and others.
Promising Parkinson’s Disease therapies include SPN-830 (apomorphine infusion pump), Tavapadon, P2B001 (extended-release pramipexole and rasagiline), ND0612 (levodopa/carbidopa), Buntanetap (ANVS401), and others.
Get a Free sample for the Parkinson’s Disease Market Forecast, Size & Share Analysis Report @ Parkinson’s Disease Therapeutics Market
Parkinson’s Disease Overview
Parkinson’s disease is a neurodegenerative disorder that predominantly affects dopamine-producing (dopaminergic) neurons in a specific area of the brain called the substantia nigra. Because the disease develops over time, it is generally classified into five stages (Stage I to Stage V) to help identify how symptoms have progressed and what to expect next. The main symptoms, referred to as parkinsonism, include tremors, bradykinesia (slowness of movement), and rigidity (muscle stiffness), which are classified as motor symptoms, while non-motor symptoms include cognitive changes, autonomic dysfunction, and mood and sleep disorders. While the exact cause is not known, a combination of genetic and environmental factors is believed to contribute to its development, and other risk factors include age, gender, head trauma, and use of certain medications. Diagnosis is challenging, as there is no definitive test or biomarker; it is typically based on medical history, symptoms, and physical and neurological examinations. MRI may be used only to exclude other causes, while DaTscan can assist in confirming the diagnosis by assessing dopamine levels in the brain. Radionuclide imaging modalities such as PET and SPECT using a dopamine transporter ligand have become the best approach to assess dopamine metabolism and deficiency.
Parkinson’s Disease Epidemiology Segmentation in the 7MM
Total Parkinson’s Disease Diagnosed Prevalent Cases
Parkinson’s Disease Age-specific Diagnosed Prevalent Cases
Parkinson’s Disease Stage-specific Diagnosed Prevalent Cases
Parkinson’s Disease Gender-specific Diagnosed Prevalent Cases
Diagnosed Prevalent Cases of Psychosis due to Parkinson’s Disease
Diagnosed Prevalent Cases of MCI due to Parkinson’s Disease
Download the report to understand which factors are driving Parkinson’s Disease Epidemiology trends @ Parkinson’s Disease Prevalence
Parkinson’s Disease Epidemiology Key Findings
In the US, total diagnosed prevalent cases of Parkinson’s disease were approximately 1,210 thousand in 2023, which is expected to increase during the forecast period (2026–2036) due to increasing awareness, an aging population, and advancement of diagnostic procedures.
DelveInsight’s epidemiology model projects nearly 695 thousand male and 517 thousand female cases in the US in 2023, with male cases outpacing female cases through 2034, reflecting a higher prevalence among men.
Among EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases with nearly 495 thousand cases in 2023, followed by France with approximately 277 thousand cases, while Spain accounted for the least with nearly 149 thousand cases.
In 2023, Japan accounted for approximately 258 thousand diagnosed prevalent cases, with approximately 135 thousand cases in males and 123 thousand cases in females.
In the US, nearly 19 thousand cases were diagnosed in the age group ≤49 years, 215 thousand cases in 50–64 years, 449 thousand cases in 65–74 years, and 527 thousand cases in ≥75 years in 2023.
Among EU4 and the UK, Stage III accounted for the highest number of cases in 2023 (nearly 409 thousand), followed by approximately 406 thousand cases in Stage II, while Stage V had the fewest with 53 thousand cases.
In Japan, stage-specific diagnosed prevalent cases in 2023 were approximately 9 thousand for Stage I, 40 thousand for Stage II, 107 thousand for Stage III, 70 thousand for Stage IV, and 31 thousand for Stage V.
In Japan, there were approximately 73 thousand cases of psychosis associated with Parkinson’s disease in 2023, while the estimated diagnosed prevalent cases of Mild Cognitive Impairment due to Parkinson’s disease in the US were nearly 508 thousand.
Approved Therapies for Parkinson’s Disease
Several approved therapies are available that primarily aim to reduce motor symptoms and improve movement. Treatment involves pharmacologic approaches, typically levodopa preparations with or without other medications, MAO-B inhibitors, COMT inhibitors, amantadine, and anticholinergics, as well as non-pharmacologic approaches such as exercise and physical, occupational, and speech therapies. Deep brain stimulation and levodopa-carbidopa enteral suspension can help individuals with medication-resistant tremors, worsening symptoms when medication wears off, and dyskinesia. Marketed therapies include CREXONT (Amneal Pharmaceuticals), PRODUODOPA (AbbVie), XADAGO/EQUFINA (Newron Pharmaceuticals/Zambon/Supernus Pharmaceuticals/Eisai), NOURIANZ/NOURIAST (Kyowa Kirin), DUOPA/DUODOPA, INBRIJA, ONGENTYS, and others.
Parkinson’s Disease Pipeline Analysis
SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals
SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion pump under the skin for 14–18 hours, with a target infusion rate of 3 mg to 8 mg per hour, intended for the continuous treatment of motor fluctuations (OFF episodes) in patients not adequately controlled with oral levodopa and one or more adjunct medications. In April 2024, the US FDA issued a CRL for the NDA, and in August 2024, Supernus Pharmaceuticals resubmitted the NDA.
Tavapadon: AbbVie (Cerevel Therapeutics)
Tavapadon is an orally bioavailable, once-daily partial agonist that selectively targets dopamine D1 and D5 receptor subtypes, designed to balance meaningful motor activity with a favourable safety profile. It has the potential to be used as monotherapy for early-stage and as adjunctive therapy for late-stage Parkinson’s disease. In April 2024, Cerevel Therapeutics reported positive topline results from the pivotal Phase III TEMPO-3 trial, and in August 2024, AbbVie completed its acquisition of Cerevel Therapeutics.
P2B001 (extended-release pramipexole and rasagiline): Pharma Two B
P2B001 is a novel, once-daily combination of extended-release pramipexole, a low-dose dopamine agonist, and rasagiline, a low-dose MAO-B inhibitor. The two drugs act through different mechanisms that complement each other, allowing lower doses without losing therapeutic effect. In November 2023, Pharma Two B published Phase III data in Movement Disorders showing that P2B001 was generally well tolerated, with fewer sleep-related and dopaminergic adverse events than commercially used doses of pramipexole ER. An NDA submission to the US FDA is currently being prepared.
Discover more about therapies set to grab Major Parkinson’s Disease Market Share @ Parkinson’s Disease Market Drivers and Barriers
Parkinson’s Disease Market Outlook
Parkinson’s disease is a progressively worsening neurodegenerative disorder with an unclear cause and pathogenesis, and its global burden is increasing, driven by aging populations and environmental factors. While no curative therapy exists, carbidopa/levodopa remains the most effective treatment, with newer formulations such as CREXONT (approved in August 2024) and RYTARY (approved in 2015) offering symptom relief, alongside DUOPA and HARUROPI TAPE (ropinirole HCL), though innovations have been limited. The market continues to face significant unmet needs, particularly for curative and disease-modifying therapies and better control of tremors, gait, balance, and psychosis. A plethora of medications are under development, including drugs targeting a-synuclein pathology, which offer hope for disease-modifying agents, and combined with regenerative approaches such as stem cells and gene therapies, therapeutics are likely to see significant advances in the coming years. Late-stage drugs expected to enter the market during the forecast period include SPN-830, Tavapadon, P2B001, and ND0612, although their success rates remain uncertain.
Parkinson’s Disease Treatment Landscape
The management of Parkinson’s disease aims at improving quality of life with symptomatic relief. Key factors driving the market include a rising prevalence due to the aging population and higher diagnosis rates, advancements in drug development and therapies across neuroprotective agents, gene therapies, and symptomatic treatments, growing adoption of advanced delivery systems such as extended-release formulations, infusion pumps, and device-assisted therapies, increased research funding and clinical trials, and rising awareness and early diagnosis programs enabling earlier intervention and wider treatment uptake.
To know more about Parkinson’s Disease Companies working in the treatment market, visit @ Parkinson’s Disease Market Access and Reimbursement
Scope of the Parkinson’s Disease Market Report
Coverage- 7MM
Study Period- 2022-2036
Forecast Period- 2026-2036
Parkinson’s Disease Companies- Amneal Pharmaceuticals, AbbVie, Newron Pharmaceuticals, Supernus Pharmaceutical, Britannia Pharmaceuticals, Pharma Two B, UCB Biopharma SRL, Novartis, Annovis Bio, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevel Therapeutics, and others.
Parkinson’s Disease Therapies- SPN-830 (apomorphine infusion pump), Tavapadon, P2B001 (extended-release pramipexole and rasagiline), ND0612 (levodopa/carbidopa), Buntanetap (ANVS401), and others.
Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and market barriers
Parkinson’s Disease Competitive Intelligence Analysis: SWOT Analysis
Parkinson’s Disease Unmet Needs, Reimbursement and Market Access
Table of Contents
Key Insights
Report Introduction
Parkinson’s Disease Market Overview at a Glance
Methodology of Parkinson’s Disease Epidemiology and Market
Executive Summary of Parkinson’s Disease
Key Events
Disease Background and Overview
Epidemiology and Patient Population
Patient Journey
Marketed Therapies
Emerging Drug Profiles
Parkinson’s Disease: Market Analysis
Key Opinion Leaders’ Views
Parkinson’s Disease SWOT Analysis
Parkinson’s Disease Unmet Needs
Parkinson’s Disease Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
